Clinical Trial Update: Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating supplementation with phosphatidylserine and omega-3 fatty acids in children with ADHD. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Omega-3 Fatty Acids (EPA/DHA) (eicosapentaenoic acid / docosahexaenoic acid)
• Phosphatidylserine (phosphatidylserine)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Attention-Deficit/Hyperactivity Disorder | Phase 2 | Status: COMPLETED